LAGUNA HILLS, Calif., April 11, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, presented data on the use of DCISionRT® to identify a subset of patients with high-risk clinicopathology who had a low 10-year risk of…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
